Authors

Sara M. Federico, MD

Latest:

Dr. Federico on Risk Categorization in Neuroblastoma

Sara M. Federico, MD, discusses risk categorization in neuroblastoma.

Julio Aguirre-Ghiso, PhD

Latest:

Dr. Aguirre-Ghiso on Future Research Directions at Albert Einstein Cancer Center

Julio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.

Rabih I. Bechara, MD, FCCP

Latest:

Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung Cancer

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

Cassie Kline, MD, MAS

Cassie Kline, MD, MAS, is

Latest:

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

Priscilla K. Brastianos, MD

Latest:

Dr Brastianos Breaks Down the Basics of Meningiomas

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

Kiavasch Mohammad Nejad Farid, MD

Kiavasch Mohammad Nejad Farid, MD, of Heidelberg University Hospital.

Latest:

Dr Farid on the Clinical Utility of Tabelecleucel in R/R EV+ PTLD

Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.

Aaron Gerds, MD, MS, Cleveland Clinic

Latest:

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

Grace Blitzer, MD

Latest:

Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth

A phase 1 trial is examining the use of mesenchymal stromal cells for treatment of radiation-induced xerostomia in patients who have completed radiation.

Michel Delforge, MD, PhD

Latest:

Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma

Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

Daniel Walden, MD

Latest:

Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRC

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

Solly Chedid, MD

Latest:

Dr. Chedid on Understanding Treatment Efficacy in Follicular Lymphoma

Solly Chedid, MD, discusses the elements of effective therapy in follicular lymphoma.

Timothy Price

Latest:

Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal Cancers

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Christos Kyriakopoulos, MD,

Latest:

Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

Omar Castaneda Puglianini, MD

Latest:

Dr. Castaneda Puglianini on Next Steps With CAR T-Cell Therapy in Multiple Myeloma

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Judith E. Hurley, MD

Latest:

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Mauricio Escobar, MD

Mauricio Escobar, MD, is an associate professor at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.

Latest:

Dr Escobar on CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

Sandra P. Susanibar-Adaniya, MD

Latest:

Dr. Susanibar on Important Considerations When Treating Multiple Myeloma

Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.

Anish Thomas, MD

Latest:

Dr. Thomas on the Rationale for the Phase 2 DDRiver SCLC 250 Trial in SCLC

Anish Thomas, MBBS, MD, medical oncologist, Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, discusses the rationale for the phase 2 DDRiver SCLC 250 trial in relapsed, platinum-resistant small cell lung cancer.

Emily M. Hinchcliff, MD, MPH

Emily M. Hinchcliff, MD, MPH, is an assistant professor at Feinberg School of Medicine, Northwestern Medicine.

Latest:

Dr Hinchcliff on the Evolving Role of ADCs in Ovarian Cancer

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

Thomas P. Frye, DO

Latest:

Exploring High-Intensity Focused Ultrasound as an Organ-Sparing Option for Prostate Cancer

The definitive treatment of prostate cancer has historically relied on whole-gland treatment.